See more : Jayden Resources Inc. (JDNRF) Income Statement Analysis – Financial Results
Complete financial analysis of Heat Biologics, Inc. (HTBX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heat Biologics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- &Do Holdings Co.,Ltd. (3457.T) Income Statement Analysis – Financial Results
- Lloyds Metals and Energy Limited (LLOYDSME.NS) Income Statement Analysis – Financial Results
- Ushakiran Finance Limited (USHAKIRA.BO) Income Statement Analysis – Financial Results
- HIM International Music Inc. (8446.TWO) Income Statement Analysis – Financial Results
- CFF FLUID CONTROL LIMITED (CFF.BO) Income Statement Analysis – Financial Results
Heat Biologics, Inc. (HTBX)
About Heat Biologics, Inc.
Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.11M | 2.95M | 3.05M | 5.79M | 1.52M | 341.64K | 0.00 | 0.00 | 0.00 | 3.11K | 187.79K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.11M | 2.95M | 3.05M | 5.79M | 1.52M | 341.64K | 0.00 | 0.00 | 0.00 | 3.11K | 187.79K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 18.82M | 12.94M | 13.01M | 16.23M | 8.27M | 9.33M | 2.60M | 2.86M | 2.74M | 902.94K | 1.25M |
| General & Administrative | 16.83M | 15.00M | 9.43M | 7.03M | 0.00 | 4.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.83M | 15.00M | 9.43M | 7.03M | 0.00 | 4.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.88M | 0.00 | 0.00 | 0.00 | 6.37M | 0.00 | 18.43M | 9.33M | 3.83M | 1.44M | 976.00K |
| Operating Expenses | 37.53M | 27.94M | 22.44M | 23.26M | 14.64M | 13.47M | 21.02M | 12.19M | 6.56M | 2.35M | 2.22M |
| Cost & Expenses | 37.53M | 27.94M | 22.44M | 23.26M | 14.64M | 13.47M | 21.02M | 12.19M | 6.56M | 2.35M | 2.22M |
| Interest Income | 815.32K | 566.72K | 431.82K | 265.75K | 22.17K | 31.14K | 66.00K | 40.57K | 10.07K | 2.00 | 517.00 |
| Interest Expense | 127.74K | 0.00 | 0.00 | 0.00 | 0.00 | 549.40K | 364.00K | 73.35K | 79.12K | 101.09K | 63.17K |
| Depreciation & Amortization | -127.74K | 333.15K | 232.51K | 237.32K | 134.08K | 132.08K | 116.00K | 66.90K | 6.35K | 2.59K | 624.00 |
| EBITDA | -35.55M | -25.72M | -19.74M | -16.48M | -12.52M | -11.89M | -19.82M | -11.65M | -8.63M | -2.32M | -2.04M |
| EBITDA Ratio | -1,682.44% | -872.35% | -647.40% | -284.47% | -823.53% | -3,480.96% | 0.00% | 0.00% | 0.00% | -74,486.40% | -1,086.92% |
| Operating Income | -35.42M | -26.12M | -20.75M | -17.96M | -13.34M | -13.13M | -21.02M | -12.19M | -6.56M | -2.34M | -2.03M |
| Operating Income Ratio | -1,676.40% | -886.18% | -680.39% | -309.99% | -877.85% | -3,842.41% | 0.00% | 0.00% | 0.00% | -75,327.23% | -1,083.57% |
| Total Other Income/Expenses | -127.74K | -257.03K | 406.27K | 383.53K | 123.44K | 152.52K | -100.00K | -56.28K | -45.22K | -108.34K | -64.18K |
| Income Before Tax | -35.55M | -26.38M | -20.34M | -17.58M | -13.22M | -12.97M | -21.12M | -12.24M | -6.61M | -2.45M | -2.10M |
| Income Before Tax Ratio | -1,682.44% | -894.90% | -667.07% | -303.37% | -869.73% | -3,797.77% | 0.00% | 0.00% | 0.00% | -78,810.87% | -1,117.75% |
| Income Tax Expense | -145.97K | -257.03K | 45.18K | -985.49K | -809.54K | 701.92K | 264.00K | 17.07K | 33.90K | -7.26K | -1.01K |
| Net Income | -35.40M | -26.05M | -20.02M | -15.73M | -11.84M | -12.57M | -20.30M | -11.79M | -8.71M | -2.42M | -2.10M |
| Net Income Ratio | -1,675.54% | -883.65% | -656.51% | -271.56% | -779.09% | -3,680.44% | 0.00% | 0.00% | 0.00% | -77,819.94% | -1,120.89% |
| EPS | -1.41 | -1.63 | -4.21 | -6.30 | -21.56 | -49.40 | -174.92 | -126.18 | -160.61 | -90.87 | -79.03 |
| EPS Diluted | -1.41 | -1.63 | -4.21 | -6.30 | -21.56 | -49.40 | -174.92 | -126.18 | -160.61 | -90.87 | -79.03 |
| Weighted Avg Shares Out | 25.14M | 15.98M | 4.75M | 2.50M | 549.33K | 254.55K | 116.02K | 93.43K | 54.24K | 26.63K | 26.63K |
| Weighted Avg Shares Out (Dil) | 25.14M | 15.98M | 4.75M | 2.50M | 549.33K | 254.55K | 116.02K | 93.43K | 54.24K | 26.63K | 26.63K |
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
Heat Biologics' Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
Heat Biologics' Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
Heat Biologics Announces Planned Transfer to the NYSE American
Heat Biologics' Merger Partner Elusys Finalizes HHS Contract For Its Anthrax Treatment
Source: https://incomestatements.info
Category: Stock Reports